A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

NCT05503927 · Enrolling by invitation

Last updated 2026-05-28

This clinical trial is testing the safety of the medication Wegovy in pregnant individuals who are overweight or obese to see how it may affect their babies.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 1,139 people Planned (estimated).

Who can join Ages 15–45 · female only

Timeline Started 2023-01 · est. completion 2027-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05503927 ↗

Description as written by the study sponsor.

This is an observational, retrospective, cohort study using administrative insurance claims data. The aim of this non-interventional study (NIS) is to compare maternal, fetal and infant outcomes of women exposed to Wegovy during pregnancy to a reference population not exposed to Wegovy, so that participants and healthcare providers can make informed treatment decisions.

Treatments tested

No Intervention Other

This is a non-interventional study, therefore no intervention is used.

Main thing measured	Number of Infants with Major Congenital Malformation (MCM)
Sponsor	Novo Nordisk A/S
Conditions studied	Pregnancy, Obesity, Overweight
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05503927 ↗